Variant Summary
- Also known as
- HIS1047ARG,RS121913279
- HGVS
- NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G
- Variant Type(s)
- missense_variant
- Evidence Items
- 26
Evidence Level Distribution
Level B: 3Level C: 3Level D: 20
Evidence Items
Showing CIViC evidence rows where gene = PIK3CA and variant = H1047R.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Pictilisib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Izorlisib | 4 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Lapatinib,Trastuzumab | 4 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Dactolisib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Dactolisib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Trastuzumab,Capivasertib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Capivasertib,Lapatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Thyroid Cancer | Perifosine,Temsirolimus | 3 |
| D | Predictive | Does Not Support | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab Emtansine | 3 |
| D | Predictive | Supports | Resistance | Colorectal Cancer | Vemurafenib | 3 |
| C | Predictive | Supports | Resistance | Colorectal Cancer | Irinotecan,Cetuximab | 3 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Lapatinib | 3 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Akt Inhibitor MK2206 | 3 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Cancer | Dactolisib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Cancer | Cetuximab,Dactolisib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Squamous Cell Carcinoma | Taselisib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Her2-receptor Positive Breast Cancer | Everolimus,Fulvestrant | 2 |
| B | Prognostic | Supports | Better Outcome | Breast Cancer | 2 | |
| B | Prognostic | Supports | Better Outcome | Breast Cancer | 2 | |
| D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Pictilisib | 2 |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 2 |
| C | Predictive | Supports | Resistance | Colorectal Cancer | Panitumumab,Cetuximab | 2 |
| D | Predictive | Supports | Resistance | Her2-receptor Positive Breast Cancer | Trastuzumab | 2 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Cancer | Dactolisib | 1 |
| D | Predictive | Supports | Sensitivity/Response | Head And Neck Cancer | Alpelisib | 1 |